
Participants:

Pr. Arne Ljungqvist, Chairman	Attending
Pr. Christiane Ayotte	Attending
Mr. Liston Bochette (replacing Mr. Alexander Popov)	Attending
Pr. Eduardo De Rose	Attending
Pr. Kenneth Fitch	Attending (Via teleconference)
Pr. Theodore Friedmann	Attending
Pr. Carlos Hamilton	Attending
Pr. Luis Horta	Attending
Pr. Ichiro Kono	Attending
Dr. Jean-Claude Mbanya	Attending
Pr. Bengt Saltin	Apologies
Dr. Patrick Schamasch	Attending
Dr. Gary Wadler, acting as Reporter for the List Committee	Attending

WADA Staff

Dr Alain Garnier
Dr Olivier Rabin
Dr Ann-Muriel Steff

1. Welcome

- Words of welcome by Richard W. Pound, David Howman and Arne Ljungqvist.

2. Introduction

- An overview of anti-doping activities carried out during the Olympic Games in Athens is made by the Chairman, Arne Ljungqvist.

3. Review of agenda

- Agenda approved.

4. Review of 2005 Prohibited List and recommendation to ExCo

- The 2005 Prohibited List prepared by the List Committee is presented by Gary Wadler.
- All changes included in the Draft 2005 Prohibited List are accepted by the HM&R Committee.
- Some topics are subjected to more detailed discussions:
 - Glucocorticosteroids
 - The Technical Paper, prepared by Dr Rochanak Mirfendereski, and the Explanatory Note prepared by the List Committee, are reviewed before presentation to the Executive Committee.
 - A mention indicating the author and the endorsement of the Technical Paper by the List Committee is added to the document.
 - Some labs report concentrations of GCs as low as 1 ng/mL. Reporting of such low concentration complicates the management of results for GCs and is not relevant to anti-doping issues.
 - It is therefore recommended that the Laboratory Committee establishes a reporting threshold for synthetic GCs. This threshold should be set so as to prevent reporting

of very low concentrations of GCs, most probably arising from non-systemic use. It is recognized that, in the absence of more detailed information on the pharmacokinetics of GCs, this threshold will be based on limited existing data from laboratories, and will be refined later with WADA-funded research projects.

- Research projects aimed at establishing urinary values of GCs according to the route administration should be encouraged by WADA.
- It is proposed that the time frame for which an athlete has to declare intake of medication on the doping control form be harmonized, and that the use of any GCs is systematically declared on the Doping Control Form.

- Discussion on miscellaneous substances
 - ACE inhibitors, pentoxifylline and buflomedil are frequently observed in urine samples. Monitoring should be performed on these substances.
 - Finasteride having been added to the 2005 List, it has to be explained to the Executive Committee that this substance is used for treating baldness, and this could cause some concerns for the attribution of TUEs.

5. Review and recommendation for the 2004 research projects

- Members of the HM&R Committee responsible for organizing the peer review process present a summary of the evaluations received in their field.
- A ranking of projects within each category is made, and 17 project are selected (see appendix 2).
- For most of the projects, budgetary revisions are recommended.
- For some projects, coupling or sharing experiments between research teams is recommended.

6. Discussion and recommendation to the Executive Committee on hypoxic chambers

- A scientific report on hypoxic chambers, evaluating their performance-enhancing capacities and their potential health risk, is being prepared by Pr Bengt Saltin.
- This report being not yet available, the topic could not be thoroughly discussed.
- It is decided that such a report is mandatory in order to provide the Executive Committee with a satisfactory recommendation on hypoxic chambers.
- The topic will also be submitted to WADA's independent Ethics Review Panel.
- As soon as the report is available, it will be circulated for review to HM&R Committee members.

7. Other items

- Christiane Ayotte raised the issues of laboratory analysis and reporting of substances covered by an abbreviated TUE (screening AND confirmation needed).
- Oliver Rabin reminded that reasons of Code compliance support such decision.

- Ted Friedmann raised the point that an education campaign is needed to inform different experts (scientists, doctors) that gene transfer aimed at improving performance is a malpractice. This issue has to be brought to the Legal and Education departments.

8. Next meeting

- Olivier Rabin mentions that there is a chance that the HM&R Committee meeting will take place only once a year in the future, due to budgetary restrictions.
- Members of the HM&R Committee recommend that the frequency of these meeting be not reduced or that the possibility of having a HM&R meeting over a period of 2 days be explored.